Mistletoe extracts are among the most studied plant-based add-on therapies in cancer care. The most coherent evidence supports a moderate improvement in quality of life and a possible easing of chemotherapy-related symptoms for some people, especially in breast cancer. Survival benefit remains unsettled. Usual under-the-skin doses are generally acceptable with expected local reactions; not a substitute for proven cancer treatment. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Complete blood count (CBC) with differential | Context-specific; support chemotherapy thresholds | Tracks marrow suppression from cancer therapy |
| ALT, AST | ALT closer to mid-normal (roughly <20–25 U/L); sustained >2× ULN triggers investigation | Detects rare hepatic stress, especially with intravenous use |
| CRP or erythrocyte sedimentation rate (ESR) | Individualize; large unexplained spikes warrant review | Contextualizes inflammatory response vs infection |
| INR (if on warfarin) | Per anticoagulation target | Rare interaction reports |
| Body temperature log | Document fever pattern post-injection | Distinguishes expected reaction from infection |
Cadence: Clinic review at first doses and during each major dose step; labs at baseline, post-escalation (≈2–4 weeks), then every 1–3 months on stable dosing, or aligned with oncology visits. Closer monitoring is typically restarted after treatment interruptions.